Determining the effects of curcumin on GDF15 gene expression and iron status in patients with beta-thalassemia intermedia
Design
A clinical trial with two groups of treatment and placebo, double-blind, randomized, phase 2-3 on 30 patients with beta-thalassemia intermedia, was selected to randomized by simple randomisation method (using a card).
Settings and conduct
patients will be divided into two groups of treatment and placebo. In this study, which will be performed double blind, physicians and patients are not aware of the distribution and taking medication or placebo. The sampling place will be Imam Reza Clinic in Shiraz. At first, 5 cc of blood is taken from the patients and after a three-month period of taking the drug or placebo, the patients will be sampled again.
Participants/Inclusion and exclusion criteria
Inclusion criteria: insensitivity to turmeric compounds, male gender, confirmation of beta-thalassemia intermedia by the relevant physician.
Exclusion criteria: diabetes, cardiovascular disease, gallbladder remove.
Intervention groups
The treatment group took 500 mg of curcumin at a dose of 1,500 mg for three months under the supervision of a physician.
The placebo group also receives the same amount of placebo in the form of 500 mg capsules with the same dose and shape of the treatment group.
Main outcome variables
Serum levels of iron, C-Reactive Protein and ferritin
General information
Reason for update
Acronym
IRCT registration information
IRCT registration number:IRCT20190902044668N1
Registration date:2020-08-10, 1399/05/20
Registration timing:prospective
Last update:2020-08-10, 1399/05/20
Update count:1
Registration date
2020-08-10, 1399/05/20
Registrant information
Name
Mohammadreza saeidnia
Name of organization / entity
Country
Iran (Islamic Republic of)
Phone
+98 84 3333 8392
Email address
m.rezasaeednia@gmail.com
Recruitment status
Recruitment complete
Funding source
Expected recruitment start date
2020-08-20, 1399/05/30
Expected recruitment end date
2020-11-19, 1399/08/29
Actual recruitment start date
empty
Actual recruitment end date
empty
Trial completion date
empty
Scientific title
Evaluation of the effects of curcumin on GDF15 gene expression and iron status in patients with beta-thalassemia intermedia
Public title
effects of curcumin on beta-thalassemia intermedia
Purpose
Treatment
Inclusion/Exclusion criteria
Inclusion criteria:
gender male
Lack of sensitivity to turmeric compounds
The beta-thalassemia intermedia is approved by the doctor.
Blood sampling in two stages before and after treatment at a rate of 5 cc
Randomization (investigator's opinion)
Randomized
Randomization description
15 cards with the intervention group code label and 15 cards with the placebo group code label were placed inside the sealed envelopes and each patient was asked to choose randomly one of these envelopes.
Blinding (investigator's opinion)
Double blinded
Blinding description
The drugs were distributed to patients in unlabeled sealed paper bags.
The main drug and the placebo drug are both taken from the pharmaceutical company, which are similar in shape, size, and color. The difference between the main drug and the placebo was not clear to the participants, The project manager will know the arrangement of the main drug and placebo.
Placebo
Used
Assignment
Parallel
Other design features
no
Secondary Ids
empty
Ethics committees
1
Ethics committee
Name of ethics committee
کمیته اخلاق دانشگاه علوم پزشکی شیراز
Street address
Meshkin Fam St. Paramedical School
City
Shiraz
Province
Fars
Postal code
71439-14693
Approval date
2020-04-19, 1399/01/31
Ethics committee reference number
IR.SUMS.REC.1399.124
Health conditions studied
1
Description of health condition studied
Intermediate beta-thalassemia
ICD-10 code
D56.1
ICD-10 code description
Beta thalassemia
Primary outcomes
1
Description
Serum iron
Timepoint
At the beginning of the study (before the intervention) and three months after the start of curcumin intake
Method of measurement
Atomic absorption spectrometry، ELISA kit
Secondary outcomes
1
Description
Serum ferritin concentrations
Timepoint
At the beginning of the study (before the intervention) and three months after the start of curcumin intake
Method of measurement
ELISA
2
Description
C-reactive protein (CRP)
Timepoint
At the beginning of the study (before the intervention) and three months after the start of curcumin intake
Method of measurement
ELISA
Intervention groups
1
Description
Intervention group: Curcumin; Each dose contains 450 mg of turmeric rhizome powder and 50 mg of turmeric extract, which is standardized based on 5.47 mg of curcumin. three months; Three doses per day orally; Dineh Pharmaceutical Company, Iran.
Category
Treatment - Drugs
2
Description
Control group: Placebo; Each dose contains 500 mg of starch or flour. three months; Three doses per orally; Dineh Iran Pharmaceutical Company.
Category
Placebo
Recruitment centers
1
Recruitment center
Name of recruitment center
درمانگاه امام رضا شهر شیراز
Full name of responsible person
Dr. Mehran Karimi
Street address
Meshkin Fam St. Paramedical School
City
Shiraz
Province
Fars
Postal code
71439-14693
Phone
+98 71 3212 7002
Fax
Email
m.rezasaeednia@gmail.com
Web page address
https://sums.ac.ir/
Sponsors / Funding sources
1
Sponsor
Name of organization / entity
Shiraz University of Medical Sciences
Full name of responsible person
Dr. Younes Ghasemi
Street address
Meshkin Fam St. Paramedical School
City
Shiraz
Province
Fars
Postal code
71348-14336
Phone
+98 71 3235 7282
Email
info@sums.ac.ir
Web page address
https://sums.ac.ir/
Grant name
no
Grant code / Reference number
ندارد
Is the source of funding the same sponsor organization/entity?
Yes
Title of funding source
Shiraz University of Medical Sciences
Proportion provided by this source
100
Public or private sector
Public
Domestic or foreign origin
Domestic
Category of foreign source of funding
empty
Country of origin
Type of organization providing the funding
Academic
Person responsible for general inquiries
Contact
Name of organization / entity
Shiraz University of Medical Sciences
Full name of responsible person
Gholamhossein Tamaddon
Position
Assistant Professor
Latest degree
Ph.D.
Other areas of specialty/work
Hematology
Street address
Meshkin Fam St. Paramedical School
City
Shiraz
Province
Fars
Postal code
71439-14693
Phone
+98 71 3227 0240
Email
tamaddon.g@gmail.com
Web page address
https://paramed.sums.ac.ir/
Person responsible for scientific inquiries
Contact
Name of organization / entity
Shiraz University of Medical Sciences
Full name of responsible person
mohammadreza saeidnia
Position
Student
Latest degree
Master
Other areas of specialty/work
Hematology
Street address
Meshkin Fam St. Paramedical School
City
Shiraz
Province
Fars
Postal code
71439-14693
Phone
+98 71 3227 0240
Email
m.rezasaeednia@gmail.com
Person responsible for updating data
Contact
Name of organization / entity
Shiraz University of Medical Sciences
Full name of responsible person
Mohammadreza saeidnia
Position
Student
Latest degree
Master
Other areas of specialty/work
Hematology
Street address
Meshkin Fam St. Paramedical School
City
Shiraz
Province
Fars
Postal code
71439-14693
Phone
+98 71 3227 0240
Email
m.rezasaeednia@gmail.com
Sharing plan
Deidentified Individual Participant Data Set (IPD)
Undecided - It is not yet known if there will be a plan to make this available
Study Protocol
Undecided - It is not yet known if there will be a plan to make this available
Statistical Analysis Plan
Not applicable
Informed Consent Form
Undecided - It is not yet known if there will be a plan to make this available
Clinical Study Report
Undecided - It is not yet known if there will be a plan to make this available
Analytic Code
Undecided - It is not yet known if there will be a plan to make this available
Data Dictionary
Undecided - It is not yet known if there will be a plan to make this available